In:
Blood, American Society of Hematology, Vol. 129, No. 12 ( 2017-03-23), p. 1636-1645
Kurzfassung:
Clofarabine integrated in standard induction therapy for newly diagnosed AML reduces relapse probability but does not improve survival. Clofarabine improves survival in intermediate-risk AML categories ELN-1 and the AML genotype without NPM1 and without FLT3-ITD gene mutations.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2016-10-740613
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2017
ZDB Id:
1468538-3
ZDB Id:
80069-7